Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioNexus Gene Lab's Enterprise Value is $0.31 Mil.
BioNexus Gene Lab's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.89 Mil. Therefore, BioNexus Gene Lab's EV-to-EBIT ratio for today is -0.11.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, BioNexus Gene Lab's Enterprise Value is $0.31 Mil.
BioNexus Gene Lab's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.72 Mil. Therefore, BioNexus Gene Lab's EV-to-EBITDA ratio for today is -0.12.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, BioNexus Gene Lab's Enterprise Value is $0.31 Mil.
BioNexus Gene Lab's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $5.31 Mil. Therefore, BioNexus Gene Lab's EV-to-Revenue ratio for today is 0.06.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
BioNexus Gene Lab (NAS:BGLC) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
BioNexus Gene Lab's current Enterprise Value is $0.31 Mil.
BioNexus Gene Lab's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.89 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
BioNexus Gene Lab's current Enterprise Value is $0.31 Mil.
BioNexus Gene Lab's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.72 Mil.
BioNexus Gene Lab's current Enterprise Value is $0.31 Mil.
BioNexus Gene Lab's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.31 Mil.
BioNexus Gene Lab's current Enterprise Value is $0.31 Mil.
BioNexus Gene Lab's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16 Mil.
BioNexus Gene Lab's current Enterprise Value is $0.31 Mil.
BioNexus Gene Lab's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab Enterprise Value Related Terms
BioNexus Gene Lab Enterprise Value Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs QGAI, VYST, GLGI: Enterprise Value Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Enterprise Value vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Enterprise Value distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
BioNexus Gene Lab's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Enterprise Value of $0.31 Mil as of Jul. 16, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on BioNexus Gene Lab and its competitors.
Is BioNexus Gene Lab's Enterprise Value too high?
BioNexus Gene Lab's current Enterprise Value is $0.31 Mil. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Enterprise Value compare to QGAI and VYST?
BioNexus Gene Lab's Enterprise Value of $0.31 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Chemicals company?
A good Enterprise Value depends on the Chemicals industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current Enterprise Value is $0.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.68 — trading 22.6% below its estimated fair value. The current Enterprise Value is $0.31 Mil. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Enterprise Value is $0.31 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.68 is trading 22.6% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Enterprise Value: $0.31 Mil
GF Value™: $2.17 vs. price of $1.68 (22.6% below fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
